Last updated on February 2018

NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

Brief description of study

NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).

Detailed Study Description

After someone has a MI, their heart 'remodels', which means that it changes in size and shape. This damage can lead to it being weaker and less efficient, and ultimately to major heart problems. There are some drugs currently available which help prevent remodelling and are used for treatment post-MI. However, there is still a high rate of remodelling and major heart problems in people post-MI. NP202 works in a different way to the drugs that are currently approved, and has been shown in animal studies to prevent post-MI remodelling.

This study will assess NP202 versus placebo on remodelling over a 3 month treatment period, with 1 month follow up

Clinical Study Identifier: NCT02557217

Find a site near you

Start Over

John Hunter Hospital

Newcastle, Australia
  Connect »